Despite recent revenue growth, the company's high P/S ratio and slower-than-industry revenue growth could risk a share price decrease. Without significant improvement in medium-term conditions, the current share price may be unreasonable.
Despite a share price drop, Tonghua Golden-Horse's high P/S suggests high investor expectations, despite weaker than average revenue growth. If P/S aligns with growth rates, shareholders may face disappointment. The company's slow revenue growth and high P/S pose a risk of share price decline.
Despite Tonghua's fair revenue rise, its high P/S ratio might imply overvaluation. Investors appear to expect substantial business improvement, ignoring its modest recent growth. Current shareholders could face disappointment if the P/S ratio aligns more with growth rates. Significant performance improvement is crucial to prevent a share price decline.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltdに関するコメント
まだコメントはありません